Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 37, Issue 8, 2018, Pages 1411-1419

  Lee, Young R ^a   Baker, Nathaniel T ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Carbapenem; Carbapenem resistant Enterobacteriaceae; CRE; Meropenem vaborbactam; Urinary tract infections; Lactamase inhibitor

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AVIBACTAM PLUS CEFTAZIDIME; BETA LACTAMASE INHIBITOR; CARBAPENEM; COLISTIN; LEVOFLOXACIN; MEROPENEM; MEROPENEM PLUS VABORBACTAM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; TIGECYCLINE; VABORBACTAM; ANTIINFECTIVE AGENT; BORONIC ACID DERIVATIVE; CARBAPENEM DERIVATIVE; THIENAMYCIN DERIVATIVE;

ABDOMINAL INFECTION; ACUTE PYELONEPHRITIS; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL PNEUMONIA; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CONTACT DERMATITIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HEADACHE; HEMATOMA; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; LETHARGY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; NAUSEA; NEPHROTOXICITY; NONHUMAN; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHLEBITIS; PLASMA CLEARANCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SINGLE DRUG DOSE; THORAX PAIN; THROMBOPHLEBITIS; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; VAGINITIS; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECT; ENTEROBACTERIACEAE INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHYSIOLOGY; TISSUE DISTRIBUTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; BORONIC ACIDS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CARBAPENEMS; CLINICAL TRIALS AS TOPIC; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; THIENAMYCINS; TISSUE DISTRIBUTION; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 85045745802     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-018-3260-4     Document Type: Review

References (29)

1. Bush K, Fisher JF (2011) Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria. Annu Rev Microbiol 65:455–478. 10.1146/annurev-micro-090110-102911
2. Patel G, Bonomo RA (2013) “Stormy waters ahead”: global emergence of carbapenemases. Front Microbiol 4(48) 10.3389/fmicb.2013.00048
3. Lagacé-Wiens P, Walkty A, Karlowsky JA (2014) Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of gram-negative bacterial infections. Core Evid 9:13–25. 10.2147/CE.S40698
4. Carbapenem-resistant Enterobacteriaceae in Healthcare Settings. CDC. https://www.cdc.gov/hai/organisms/cre/index.html. Accessed 27 Nov 2017
5. Sabet M, Tarazi Z, Rubio-Aparicio D et al (2018) Activity of simulated human dosage regimens of meropenem and vaborbactam against carbapenem-resistant Enterobacteriaceae in an in vitro hollow-fiber model. Antimicrob Agents Chemother 62(2):e01969-17 10.1128/AAC.01969-17
6. Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF (2017) Evaluation of the in vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob Agents Chemother 62(1):e01904–e01917 10.1128/AAC.01904-17
7. Griffith DC, Rubino C, Loutit JS, Morgan EE, White D, Dudley MN (2014) A phase 1 study of the safety, tolerability, and pharmacokinetics of a single dose of the beta-lactamase inhibitor RPX7009 alone, meropenem alone, and both in combination (Carbavance) in healthy adult subjects. Abstract F-960. 54th Intersci Conf Antimicrob Agents Chemother; American Society of Microbiology, Washington D.C
8. Wenzler E, Gotfried MH, Loutit JS et al (2015) Meropenem-RPX7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects. Antimicrob Agents Chemother 59(12):7232–7239 10.1128/AAC.01713-15
9. Griffith DC, Loutit JS, Morgan EE, Durso S, Dudley MN (2016) Phase 1 study of the safety, tolerability, and pharmacokinetics of the β-lactamase inhibitor vaborbactam (RPX7009) in healthy adult subjects. Antimicrob Agents Chemother 60(10):6326–6332 10.1128/AAC.00568-16
10. Rubino CM, Bhavnani SM, Loutit JS, Lohse B, Dudley MN, Griffith DC (2018) Single-dose pharmacokinetics and safety of meropenem-vaborbactam in subjects with chronic renal impairment. Antimicrob Agents Chemother 62(3):e02103-17 10.1128/AAC.02103-17
11. Kaye KS, Bhowmick T, Metallidis S et al (2018) Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA 319(8):788–799 10.1001/jama.2018.0438
12. Kaye KS, Vazquez J, Mathers A et al (2017) Meropenem-vaborbactam (VABOMERE) vs. best available therapy for CRE infections: TANGO II randomized, controlled phase 3 study results abstract. IDWeek, San Diego, p 1862
13. Weiss WJ, Pulse ME, Nguyen P et al (2017) Activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae in a murine model of pyelonephritis. Antimicrob Agents Chemother 62(1):e01439-17 10.1128/AAC.01439-17
14. Sabet M, Tarazi Z, Nolan T et al (2017) Activity of meropenem-vaborbactam in mouse models of infection due to KPC-producing carbapenem-resistant Enterobacteriaceae (CRE). Antimicrob Agents Chemother 62(1). 10.1128/AAC.01446-17
15. Hecker SJ, Reddy KR, Totrov M et al (2015) Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem 58(9):3682–3692. 10.1021/acs.jmedchem.5b00127
16. Zhanel GG, Wiebe R, Dilay L et al (2007) Comparative review of the carbapenems. Drugs 67(7):1027–1052
17. Bush K (2015) A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant gram-negative pathogens. Int J Antimicrob Agents 46(5):483–493. 10.1016/j.ijantimicag.2015.08.011
18. Codjoe FS, Donkor ES (2017) Carbapenem resistance: a review. Med Sci (Basel) 6(1). 10.3390/medsci6010001
19. Lomovskaya O, Sun D, Rubio-Aparicio D et al (2017) Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother 61(11). 10.1128/AAC.01443-17
20. Lomovskaya O, Tsivkovski R (2014) The effect of Trp105 substitutions in KPC on interactions with the novel beta-lactamase inhibitor RPX7009 Abstract C-1194. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; American Society of Microbiology, Washington D.C
21. Lapuebla A, Abdallah M, Olafisoye O et al (2015) Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against gram-negative clinical isolates in New York City. Antimicrob Agents Chemother 59(8):4856–4860 10.1128/AAC.00843-15
22. Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M (2018) In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program. Int J Antimicrob Agents pii S0924-8579(18):30064–30065 10.1016/j.ijantimicag.2018.02.021
23. Castanheira M, Huband MD, Mendes RE, Flamm RK (2017) Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother 61(9):e00567-17 10.1128/AAC.00567-17
24. Sun D, Rubio-Aparicio D, Nelson K, Dudley MN, Lomovskaya O (2017) Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 61(12):e01694-17 10.1128/AAC.01694-17
25. Haidar G, Clancy CJ, Shields RK, Hao B, Cheng S, Nguyen MH (2017) Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum β-lactamases. Antimicrob Agents Chemother 61(5):e02534-16 10.1128/AAC.02534-16
26. MERREM® I.V. (meropenem for injection) package insert. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050706s022lbl.pdf. Accessed 17 Nov 2017
27. Zhanel GG, Simor AE, Vercaigne L, Mandell L, Group CCD (1998) Imipenem and meropenem: comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. Can J Infect Dis 9(4):215–228
28. VABOMERE™ (meropenem and vaborbactam) for injection. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209776lbl.pdf. Accessed 17 Nov 2017
29. Wunderink R, Giamarellos-Bourboulis EJ, Rahav G et al (2017) Meropenem-vaborbactam (VABOMERE) vs. best available therapy for carbapenem-resistant Enterobacteriaceae infections in TANGO II: primary outcomes by site of infection abstract. IDWeek, San Diego, p 1867